Cepmox is a potent third-generation cephalosporin antibiotic formulated for the targeted treatment of moderate to severe bacterial infections. Its advanced β-lactam structure ensures high bactericidal activity against a wide range of Gram-positive and Gram-negative pathogens. Clinically trusted for its reliable pharmacokinetic profile and low resistance development, Cepmox is a first-line choice in both hospital and community settings for combating complex infections. It offers rapid tissue penetration and sustained serum concentrations, making it indispensable in empirical and directed antimicrobial therapy.

Features

• Contains cefpodoxime proxetil 200 mg per film-coated tablet
• Exhibits broad-spectrum activity against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, and Klebsiella species
• High oral bioavailability with approximately 50% absorption unaffected by food
• Plasma half-life of 2–3 hours allowing for twice-daily dosing
• Excreted largely unchanged in urine, with 80% renal clearance within 24 hours
• Manufactured under GMP conditions with shelf stability of 36 months

Benefits

• Rapid onset of action with measurable bactericidal effects within 2 hours of administration
• High clinical cure rates in respiratory, urinary, and skin structure infections
• Convenient dosing schedule improves patient adherence and reduces treatment failure
• Lower propensity for resistance development compared to earlier-generation cephalosporins
• Well-tolerated profile with minimal disruption to gastrointestinal flora
• Cost-effective therapy due to reduced hospitalization needs and shorter treatment duration

Common use

Cepmox is indicated for the treatment of acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated urinary tract infections, acute otitis media, pharyngitis, tonsillitis, and uncomplicated skin and skin structure infections. It is particularly effective against β-lactamase-producing strains, making it suitable for regions with high resistance patterns. Off-label use may include gonococcal infections and prophylaxis in immunocompromised patients, though under strict medical supervision.

Dosage and direction

Adults and children ≥12 years: 200 mg orally every 12 hours for 7–14 days depending on infection severity.
Renal impairment (CrCl <30 mL/min): 200 mg every 24 hours.
Administration: May be taken with or without food; tablets should be swallowed whole with water.
Complete the full prescribed course even if symptoms improve earlier to prevent recurrence and resistance.

Precautions

• Use with caution in patients with history of gastrointestinal disease, particularly colitis
• Monitor renal function periodically during prolonged therapy
• May cause false-positive urinary glucose tests when using copper reduction methods
• Superinfections with fungi or resistant bacteria may occur with extended use
• Not recommended during pregnancy unless potential benefit justifies potential risk (Category B)

Contraindications

• Known hypersensitivity to cefpodoxime, other cephalosporins, or any component of the formulation
• Patients with previous anaphylactic reactions to β-lactam antibiotics
• Severe renal impairment without dosage adjustment
• Concurrent administration with probenecid

Possible side effects

Common (≥1%): diarrhea, nausea, headache, vaginal mycosis.
Less common (<1%): abdominal pain, vomiting, dizziness, rash, transient elevation of liver enzymes.
Rare: pseudomembranous colitis, eosinophilia, neutropenia, Stevens-Johnson syndrome, anaphylaxis.

Drug interaction

• Probenecid: Concurrent use may increase and prolong cefpodoxime serum levels
• Antacids and H₂ blockers: Reduce absorption; administer at least 2 hours apart
• Oral anticoagulants: Potential enhancement of anticoagulant effect
• Other nephrotoxic drugs: May increase risk of renal impairment

Missed dose

Take the missed dose as soon as remembered unless it is almost time for the next dose. Do not double the dose to catch up. Maintain the regular dosing schedule to ensure consistent therapeutic levels.

Overdose

Symptoms may include nausea, vomiting, epigastric distress, diarrhea, and convulsions. Management includes gastric lavage and supportive care. Hemodialysis may remove approximately 30% of the administered dose.

Storage

Store below 25°C in original packaging protected from light and moisture. Keep out of reach of children. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is intended for medical professionals and should not replace clinical judgment. Always verify dosage and suitability based on individual patient factors, local guidelines, and culture/sensitivity reports. The prescriber assumes full responsibility for appropriate patient selection and monitoring.

Reviews

“Cepmox has become our go-to oral cephalosporin for resistant respiratory infections. We observe consistent microbial eradication and excellent patient tolerance.” – Dr. Elena Rostova, Infectious Disease Specialist

“In our pediatric practice, Cepmox shows remarkable efficacy in otitis media with once-daily dosing in older children. Minimal GI upset reported.” – Children’s Health Network, Clinical Report

“Compared to other oral antibiotics, Cepmox offers superior penetration into lung tissue and reliable coverage for common pathogens in COPD exacerbations.” – Pulmonology Today, Vol. 12